Copyright Reports & Markets. All rights reserved.

Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Research Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Overview

      • 1.1 Product Overview and Scope of Squamous Non-Small Cell Lung Cancer Therapeutics
      • 1.2 Squamous Non-Small Cell Lung Cancer Therapeutics Segment by Type
        • 1.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Production Growth Rate Comparison by Type (2014-2025)
        • 1.2.2 BMS-906024
        • 1.2.3 Buparlisib Hydrochloride
        • 1.2.4 FP-1039
        • 1.2.5 Ipilimumab
        • 1.2.6 JNJ-42756493
        • 1.2.7 Lenvatinib
        • 1.2.8 Others
      • 1.3 Squamous Non-Small Cell Lung Cancer Therapeutics Segment by Application
        • 1.3.1 Squamous Non-Small Cell Lung Cancer Therapeutics Consumption Comparison by Application (2014-2025)
        • 1.3.2 Research Center
        • 1.3.3 Hospital
        • 1.3.4 Clinic
      • 1.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market by Region
        • 1.3.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Region
        • 1.3.2 North America Status and Prospect (2014-2025)
        • 1.3.3 Europe Status and Prospect (2014-2025)
        • 1.3.4 China Status and Prospect (2014-2025)
        • 1.3.5 Japan Status and Prospect (2014-2025)
        • 1.3.6 Southeast Asia Status and Prospect (2014-2025)
        • 1.3.7 India Status and Prospect (2014-2025)
      • 1.4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size
        • 1.4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2014-2025)
        • 1.4.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Production (2014-2025)

      2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Competition by Manufacturers

      • 2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Production Market Share by Manufacturers (2014-2019)
      • 2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Share by Manufacturers (2014-2019)
      • 2.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Average Price by Manufacturers (2014-2019)
      • 2.4 Manufacturers Squamous Non-Small Cell Lung Cancer Therapeutics Production Sites, Area Served, Product Types
      • 2.5 Squamous Non-Small Cell Lung Cancer Therapeutics Market Competitive Situation and Trends
        • 2.5.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Rate
        • 2.5.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Share of Top 3 and Top 5 Manufacturers
        • 2.5.3 Mergers & Acquisitions, Expansion

      3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Production Market Share by Regions

      • 3.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Production Market Share by Regions
      • 3.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Regions (2014-2019)
      • 3.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.4 North America Squamous Non-Small Cell Lung Cancer Therapeutics Production
        • 3.4.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Production Growth Rate (2014-2019)
        • 3.4.2 North America Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.5 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Production
        • 3.5.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Production Growth Rate (2014-2019)
        • 3.5.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.6 China Squamous Non-Small Cell Lung Cancer Therapeutics Production (2014-2019)
        • 3.6.1 China Squamous Non-Small Cell Lung Cancer Therapeutics Production Growth Rate (2014-2019)
        • 3.6.2 China Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.7 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Production (2014-2019)
        • 3.7.1 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Production Growth Rate (2014-2019)
        • 3.7.2 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)

      4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Consumption by Regions

      • 4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Consumption by Regions
      • 4.2 North America Squamous Non-Small Cell Lung Cancer Therapeutics Consumption (2014-2019)
      • 4.3 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Consumption (2014-2019)
      • 4.4 China Squamous Non-Small Cell Lung Cancer Therapeutics Consumption (2014-2019)
      • 4.5 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Consumption (2014-2019)

      5 Global Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Price Trend by Type

      • 5.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Production Market Share by Type (2014-2019)
      • 5.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2014-2019)
      • 5.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Price by Type (2014-2019)
      • 5.4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Production Growth by Type (2014-2019)

      6 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Analysis by Applications

      • 6.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Consumption Market Share by Application (2014-2019)
      • 6.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Consumption Growth Rate by Application (2014-2019)

      7 Company Profiles and Key Figures in Squamous Non-Small Cell Lung Cancer Therapeutics Business

      • 7.1 Ascenta Therapeutics, Inc.
        • 7.1.1 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Production Sites and Area Served
        • 7.1.2 Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction, Application and Specification
        • 7.1.3 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.1.4 Main Business and Markets Served
      • 7.2 AstraZeneca Plc
        • 7.2.1 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Production Sites and Area Served
        • 7.2.2 Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction, Application and Specification
        • 7.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.2.4 Main Business and Markets Served
      • 7.3 AVEO Pharmaceuticals, Inc.
        • 7.3.1 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Production Sites and Area Served
        • 7.3.2 Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction, Application and Specification
        • 7.3.3 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.3.4 Main Business and Markets Served
      • 7.4 Bayer AG
        • 7.4.1 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Production Sites and Area Served
        • 7.4.2 Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction, Application and Specification
        • 7.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.4.4 Main Business and Markets Served
      • 7.5 BIND Therapeutics, Inc.
        • 7.5.1 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Production Sites and Area Served
        • 7.5.2 Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction, Application and Specification
        • 7.5.3 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.5.4 Main Business and Markets Served
      • 7.6 Boehringer Ingelheim GmbH
        • 7.6.1 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Production Sites and Area Served
        • 7.6.2 Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction, Application and Specification
        • 7.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.6.4 Main Business and Markets Served
      • 7.7 Bristol-Myers Squibb Company
        • 7.7.1 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Production Sites and Area Served
        • 7.7.2 Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction, Application and Specification
        • 7.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.7.4 Main Business and Markets Served
      • 7.8 Eli Lilly and Company
        • 7.8.1 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Production Sites and Area Served
        • 7.8.2 Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction, Application and Specification
        • 7.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.8.4 Main Business and Markets Served
      • 7.9 F. Hoffmann-La Roche Ltd.
        • 7.9.1 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Production Sites and Area Served
        • 7.9.2 Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction, Application and Specification
        • 7.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.9.4 Main Business and Markets Served
      • 7.10 Five Prime Therapeutics, Inc.
        • 7.10.1 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Production Sites and Area Served
        • 7.10.2 Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction, Application and Specification
        • 7.10.3 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.10.4 Main Business and Markets Served
      • 7.11 Genentech, Inc.
      • 7.12 Incyte Corporation
      • 7.13 Johnson & Johnson
      • 7.14 MacroGenics, Inc.
      • 7.15 Novartis AG
      • 7.16 Oncogenex Pharmaceuticals, Inc.
      • 7.17 PsiOxus Therapeutics Limited

      8 Squamous Non-Small Cell Lung Cancer Therapeutics Manufacturing Cost Analysis

      • 8.1 Squamous Non-Small Cell Lung Cancer Therapeutics Key Raw Materials Analysis
        • 8.1.1 Key Raw Materials
        • 8.1.2 Price Trend of Key Raw Materials
        • 8.1.3 Key Suppliers of Raw Materials
      • 8.2 Proportion of Manufacturing Cost Structure
      • 8.3 Manufacturing Process Analysis of Squamous Non-Small Cell Lung Cancer Therapeutics
      • 8.4 Squamous Non-Small Cell Lung Cancer Therapeutics Industrial Chain Analysis

      9 Marketing Channel, Distributors and Customers

      • 9.1 Marketing Channel
        • 9.1.1 Direct Marketing
        • 9.1.2 Indirect Marketing
      • 9.2 Squamous Non-Small Cell Lung Cancer Therapeutics Distributors List
      • 9.3 Squamous Non-Small Cell Lung Cancer Therapeutics Customers

      10 Market Dynamics

      • 10.1 Market Trends
      • 10.2 Opportunities
      • 10.3 Market Drivers
      • 10.4 Challenges
      • 10.5 Influence Factors

      11 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Forecast

      • 11.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue Forecast
        • 11.1.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Production Growth Rate Forecast (2019-2025)
        • 11.1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate Forecast (2019-2025)
        • 11.1.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Price and Trend Forecast (2019-2025)
      • 11.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Production Forecast by Regions (2019-2025)
        • 11.2.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2019-2025)
        • 11.2.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2019-2025)
        • 11.2.3 China Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2019-2025)
        • 11.2.4 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2019-2025)
      • 11.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Consumption Forecast by Regions (2019-2025)
        • 11.3.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Consumption Forecast (2019-2025)
        • 11.3.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Consumption Forecast (2019-2025)
        • 11.3.3 China Squamous Non-Small Cell Lung Cancer Therapeutics Consumption Forecast (2019-2025)
        • 11.3.4 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Consumption Forecast (2019-2025)
      • 11.4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Production, Revenue and Price Forecast by Type (2019-2025)
      • 11.5 Global Squamous Non-Small Cell Lung Cancer Therapeutics Consumption Forecast by Application (2019-2025)

      12 Research Findings and Conclusion

        13 Methodology and Data Source

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        The global Squamous Non-Small Cell Lung Cancer Therapeutics market is valued at million US$ in 2018 is expected to reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
        This report focuses on Squamous Non-Small Cell Lung Cancer Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Squamous Non-Small Cell Lung Cancer Therapeutics market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
        At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

        The following manufacturers are covered:
        Ascenta Therapeutics, Inc.
        AstraZeneca Plc
        AVEO Pharmaceuticals, Inc.
        Bayer AG
        BIND Therapeutics, Inc.
        Boehringer Ingelheim GmbH
        Bristol-Myers Squibb Company
        Eli Lilly and Company
        F. Hoffmann-La Roche Ltd.
        Five Prime Therapeutics, Inc.
        Genentech, Inc.
        Incyte Corporation
        Johnson & Johnson
        MacroGenics, Inc.
        Novartis AG
        Oncogenex Pharmaceuticals, Inc.
        PsiOxus Therapeutics Limited

        Segment by Regions
        North America
        Europe
        China
        Japan

        Segment by Type
        BMS-906024
        Buparlisib Hydrochloride
        FP-1039
        Ipilimumab
        JNJ-42756493
        Lenvatinib
        Others

        Segment by Application
        Research Center
        Hospital
        Clinic

        Buy now